IRON
Disc Medicine, Inc. Health Care Pharmaceutical Preparations Russell 3000
$80.84Close
$3.1BMarket cap
$55.74 – $94.1152-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
14%
1wk
up 8.5%
price change
1mo
up 23.5%
price change
12-month return
down 6%
market up 11% ·
its own down 16%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
4.1×
price / book
Earnings yield
down 7.9%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 36%
return on equity
Free cash margin
—
-$181.3M FCF
D/E
0.04
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.1%
$4.11 a day · 2×ATR $72.62
RS
56 / 99
vs the universe
Trend
5 / 8
200-day not rising, 50-day under the 150/200-day, RS under 70
Relative volume
0.7×
vs 50-day average
Up/down volume
0.95
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 5 of 8
- Price above the 150 and 200-day averages: passes
- 150-day average above the 200-day: passes
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: passes
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 26.9% over the year, from 30m to 38m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Oct 22, 2026
Results reaction
Oct 22, 20260% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$34.0M | -$30.9M | -$47.5M | -$91.1M | -$129.7M | -$236.0M |
| Net income | -$40.8M | -$36.0M | -$46.8M | -$76.4M | -$109.4M | -$212.2M |
| Earnings per share | — | -$40.95 | -$45.05 | -$3.42 | -$3.96 | -$6.01 |
| Free cash flow | -$32.7M | -$27.6M | -$42.4M | -$73.6M | -$94.4M | -$181.3M |
| Cash | $4.5M | $88.0M | $194.6M | $360.4M | $192.4M | $91.1M |
| Long-term debt | $14.0M | $404,000 | — | $0 | $28.3M | $29.2M |
| Shareholders' equity | -$28.8M | -$64.2M | $176.6M | $345.1M | $443.6M | $739.8M |
| Shares outstanding | 15.57m | 909.42k | 17.40m | 24.36m | 29.87m | 37.89m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 21, 2024 | Annual ↗ | Dec 31, 2023 | 81d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 22, 2026 | Material agreement · Results · Other events ↗ |
| Oct 19, 2026 | Regulation FD · Other events ↗ |
| Sep 10, 2026 | Regulation FD · Other events ↗ |
| Jul 30, 2026 | Results ↗ |
| Jun 30, 2026 | Material agreement · New obligation ↗ |
| Jun 24, 2026 | Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Feb 27, 2026 | Restructuring ↗ |
| Feb 26, 2026 | Results ↗ |
| Feb 17, 2026 | Regulation FD ↗ |
| Feb 13, 2026 | Regulation FD · Other events ↗ |
| Jan 12, 2026 | Results · Regulation FD ↗ |